Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia

Ronan Swords, Yesid Alvarado, Jorge Cortes, Francis J. Giles

Research output: Contribution to journalReview article

Abstract

Chronic myeloid leukemia (CML) was the first human malignancy to be associated with a single genetic abnormality, characterized by a reciprocal translocation involving chromosomes 9 and 22 (the Philadelphia chromosome). The fusion gene that results (BCR-ABL) produces a constitutively activated tyrosine kinase that exists in different isoforms depending on BCR breakpoints. Imatinib mesylate is a highly selective inhibitor of this kinase, producing normal blood counts in 98% of patients in chronic phase CML and disappearance of the Philadelphia chromosome in 86%. However, 17% of patients in the chronic phase will either relapse or develop resistance resulting mainly from one or more point mutations affecting at least 30 amino acids within the Abl kinase protein. This review focuses on the relevant biology of CML, imatinib mesylate resistance mechanisms, and the current status of the next generation of Bcr-Abl inhibitors.

Original languageEnglish (US)
Pages (from-to)83-88
Number of pages6
JournalCurrent Hematologic Malignancy Reports
Volume2
Issue number2
DOIs
StatePublished - Apr 1 2007
Externally publishedYes

Fingerprint

Philadelphia Chromosome
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Leukemia, Myeloid, Chronic Phase
Chromosomes, Human, Pair 22
Chromosomes, Human, Pair 9
Gene Fusion
Point Mutation
Protein Kinases
Protein Isoforms
Phosphotransferases
Amino Acids
Recurrence
Therapeutics
Neoplasms
Imatinib Mesylate

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia. / Swords, Ronan; Alvarado, Yesid; Cortes, Jorge; Giles, Francis J.

In: Current Hematologic Malignancy Reports, Vol. 2, No. 2, 01.04.2007, p. 83-88.

Research output: Contribution to journalReview article

Swords, Ronan ; Alvarado, Yesid ; Cortes, Jorge ; Giles, Francis J. / Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia. In: Current Hematologic Malignancy Reports. 2007 ; Vol. 2, No. 2. pp. 83-88.
@article{b59af41559694b3ca5ef1d1cda3319f9,
title = "Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia",
abstract = "Chronic myeloid leukemia (CML) was the first human malignancy to be associated with a single genetic abnormality, characterized by a reciprocal translocation involving chromosomes 9 and 22 (the Philadelphia chromosome). The fusion gene that results (BCR-ABL) produces a constitutively activated tyrosine kinase that exists in different isoforms depending on BCR breakpoints. Imatinib mesylate is a highly selective inhibitor of this kinase, producing normal blood counts in 98{\%} of patients in chronic phase CML and disappearance of the Philadelphia chromosome in 86{\%}. However, 17{\%} of patients in the chronic phase will either relapse or develop resistance resulting mainly from one or more point mutations affecting at least 30 amino acids within the Abl kinase protein. This review focuses on the relevant biology of CML, imatinib mesylate resistance mechanisms, and the current status of the next generation of Bcr-Abl inhibitors.",
author = "Ronan Swords and Yesid Alvarado and Jorge Cortes and Giles, {Francis J.}",
year = "2007",
month = "4",
day = "1",
doi = "10.1007/s11899-007-0012-4",
language = "English (US)",
volume = "2",
pages = "83--88",
journal = "Current Hematologic Malignancy Reports",
issn = "1558-8211",
publisher = "Springer Science + Business Media",
number = "2",

}

TY - JOUR

T1 - Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia

AU - Swords, Ronan

AU - Alvarado, Yesid

AU - Cortes, Jorge

AU - Giles, Francis J.

PY - 2007/4/1

Y1 - 2007/4/1

N2 - Chronic myeloid leukemia (CML) was the first human malignancy to be associated with a single genetic abnormality, characterized by a reciprocal translocation involving chromosomes 9 and 22 (the Philadelphia chromosome). The fusion gene that results (BCR-ABL) produces a constitutively activated tyrosine kinase that exists in different isoforms depending on BCR breakpoints. Imatinib mesylate is a highly selective inhibitor of this kinase, producing normal blood counts in 98% of patients in chronic phase CML and disappearance of the Philadelphia chromosome in 86%. However, 17% of patients in the chronic phase will either relapse or develop resistance resulting mainly from one or more point mutations affecting at least 30 amino acids within the Abl kinase protein. This review focuses on the relevant biology of CML, imatinib mesylate resistance mechanisms, and the current status of the next generation of Bcr-Abl inhibitors.

AB - Chronic myeloid leukemia (CML) was the first human malignancy to be associated with a single genetic abnormality, characterized by a reciprocal translocation involving chromosomes 9 and 22 (the Philadelphia chromosome). The fusion gene that results (BCR-ABL) produces a constitutively activated tyrosine kinase that exists in different isoforms depending on BCR breakpoints. Imatinib mesylate is a highly selective inhibitor of this kinase, producing normal blood counts in 98% of patients in chronic phase CML and disappearance of the Philadelphia chromosome in 86%. However, 17% of patients in the chronic phase will either relapse or develop resistance resulting mainly from one or more point mutations affecting at least 30 amino acids within the Abl kinase protein. This review focuses on the relevant biology of CML, imatinib mesylate resistance mechanisms, and the current status of the next generation of Bcr-Abl inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=34248401176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248401176&partnerID=8YFLogxK

U2 - 10.1007/s11899-007-0012-4

DO - 10.1007/s11899-007-0012-4

M3 - Review article

C2 - 20425355

AN - SCOPUS:34248401176

VL - 2

SP - 83

EP - 88

JO - Current Hematologic Malignancy Reports

JF - Current Hematologic Malignancy Reports

SN - 1558-8211

IS - 2

ER -